The Institute for Clinical and Economic Review (ICER) announced Thursday, Dec. 5, plans to review Bluebird Bio’s LentiGlobin, a gene therapy used to treat beta thalassemia.
According to a press release, the Food and Drug Administration is expected to make a decision on the drug late next year. The drug is currently in the European market.
A draft scoping document for the planned review is set to be available on Jan. 6, 2020.
To read the full press release, click here.